BillionToOne: A Closer Look at the Biotech Stock Surge

Menlo Park-based biotech company sees significant growth

Stock Price Surge

• Current Price: $130.18 (as of Friday)
• IPO Price: $60
• Market Valuation: $5.91 billion

Recent Fundraising

• Amount Raised: $273 million
• Shares Sold: 4.55 million
• Price Range: $49 - $55 per share
• Outcome: Exceeded initial plans, indicating strong investor interest.

Analyst Sentiment

Bullish Views

• Piper Sandler:
• Rating: Overweight
• Price Target: $150
• Commentary: Oncology liquid biopsy products described as "game-changing" for therapy selection and monitoring.
• J. P. Morgan:
• Focus: Pipeline, including a tissue-free minimal residual disease test expected in 2026.
• Outlook: Key driver for long-term growth.

Cautious Views

• Jefferies:
• Rating: Hold
• Concern: Current share price reflects a lot of future growth.
• Acknowledgment: Strong technology but cautioned that success in cancer testing will take time.

Company Overview

• Founded: 2016
• Technology: Non-invasive prenatal and oncology blood tests using proprietary single-molecule next-generation sequencing technology.

Financial Performance

• Revenue Growth: Nearly 82% increase in the six months ended June 30, compared to the previous year.
• Gross Profit: More than doubled over the same period.